Silverleafe Capital Partners LLC Makes New $939,000 Investment in Tempus AI, Inc. $TEM

Silverleafe Capital Partners LLC acquired a new stake in Tempus AI, Inc. (NASDAQ:TEM) in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm acquired 15,897 shares of the company’s stock, valued at approximately $939,000.

Several other hedge funds and other institutional investors have also recently modified their holdings of TEM. Cranbrook Wealth Management LLC acquired a new position in shares of Tempus AI during the third quarter worth approximately $25,000. JPL Wealth Management LLC acquired a new stake in Tempus AI in the 3rd quarter valued at $26,000. GAMMA Investing LLC bought a new stake in Tempus AI during the 3rd quarter valued at $28,000. Harvest Fund Management Co. Ltd bought a new stake in Tempus AI during the 3rd quarter valued at $38,000. Finally, Tsfg LLC raised its holdings in Tempus AI by 1,515.2% during the third quarter. Tsfg LLC now owns 533 shares of the company’s stock worth $43,000 after buying an additional 500 shares during the last quarter. Institutional investors own 24.22% of the company’s stock.

Analyst Ratings Changes

A number of research analysts have recently issued reports on TEM shares. Needham & Company LLC reiterated a “buy” rating and set a $75.00 price objective on shares of Tempus AI in a report on Wednesday, March 11th. BTIG Research cut their price target on Tempus AI from $105.00 to $90.00 and set a “buy” rating for the company in a research note on Wednesday, February 25th. Morgan Stanley decreased their price objective on Tempus AI from $85.00 to $70.00 and set an “overweight” rating for the company in a report on Tuesday, March 3rd. Mizuho assumed coverage on Tempus AI in a research note on Thursday, February 19th. They issued an “outperform” rating and a $100.00 price objective for the company. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Tempus AI in a report on Thursday, January 22nd. Eight investment analysts have rated the stock with a Buy rating, four have issued a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $78.62.

Tempus AI Stock Performance

NASDAQ TEM opened at $46.76 on Thursday. The company has a market capitalization of $8.36 billion, a PE ratio of -33.16 and a beta of 5.29. The company has a debt-to-equity ratio of 2.52, a quick ratio of 3.00 and a current ratio of 3.13. Tempus AI, Inc. has a 52-week low of $36.22 and a 52-week high of $104.32. The company has a 50-day simple moving average of $56.13 and a 200 day simple moving average of $70.16.

Insider Activity

In other news, CEO Eric P. Lefkofsky sold 166,250 shares of the company’s stock in a transaction on Wednesday, January 28th. The stock was sold at an average price of $65.56, for a total transaction of $10,899,350.00. Following the transaction, the chief executive officer owned 8,941,533 shares of the company’s stock, valued at $586,206,903.48. This represents a 1.83% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, EVP Erik Phelps sold 9,464 shares of Tempus AI stock in a transaction dated Thursday, February 19th. The stock was sold at an average price of $59.43, for a total value of $562,445.52. Following the completion of the sale, the executive vice president directly owned 79,816 shares of the company’s stock, valued at approximately $4,743,464.88. This trade represents a 10.60% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last three months, insiders have sold 402,591 shares of company stock worth $24,868,936. 26.27% of the stock is owned by company insiders.

Tempus AI Profile

Tempus is a technology-driven healthcare company that applies artificial intelligence and machine learning to clinical and molecular data in order to advance precision medicine. Its primary focus lies in oncology, where the company offers comprehensive genomic profiling, digital pathology services and data-driven insights to inform personalized cancer care. By integrating DNA and RNA sequencing with structured clinical information, Tempus enables clinicians and researchers to identify targeted treatment options for patients based on the genetic characteristics of their tumors.

The company’s core offering centers on a scalable, cloud-based analytics platform that aggregates vast amounts of molecular and clinical data.